News

Human connective tissue mast cells A cellular model to better understand the underlying mechanisms of Injection Site Reactions (ISRs) and other severe allergic reactions. Mast cell culture assays are critical to better understand the kinetics and dynamics underlying inflammatory reactions. Genoskin’s team of experts has developed a method to grow connective tissue-type mast cells (CTMCs) derived from the peripheral bloodRead more

Top things found in human skin (vs in reconstructed human skin models) Skin is our largest organ (2m2). Since the skin is a mandatory test organ for regulatory agencies, every single drug in development needs to be tested for potential skin toxicity. Today, efficacy and safety studies are performed either on animal skin, reconstructed skin, or ex vivo human skin.Read more

The FlowSkin® platform : a unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin When human tissue culture meets microfluidic technology, it leads to the first perfused human skin model ; an amazing platform to overcome the challenges of drug development and replace animal testing. Almost 10 years ago now, Genoskin developed theRead more

Genoskin awarded the Healthtech prize “Transformons la France!” Yesterday, Genoskin was awarded the Healthtech prize at the “Transformons la France!” (Let’s Transform France!) ceremony presented by La Tribune in Toulouse. While the current health crisis calls into question our lifestyles, "Transformons la France!" highlights the talents of tomorrow and gives impact to those who transform society for the better. TheRead more

Genoskin interviewed by the National Anti-Vivisection Society on alternatives to animal testing Genoskin’s Chief Commercial Officer, Eric Merle, recently had the opportunity to speak with the National Anti-Vivisection Society (NAVS). Through a Q&A, Eric explains why Genoskin’s ex vivo human skin assays are a reliable alternative to animal testing. “We generate human data” Even though testing new drugs and compoundsRead more

Genoskin & LEO Pharma publish data on inflammation model InflammaSkin® in Experimental Dermatology Genoskin’s amazing team of experts is always developing new and improved ex vivo human skin assays. This time, we partnered with LEO Pharma to develop a brand new inflammation model: InflammaSkin®. Genoskin is proud to announce that its unique skin assay is now fully described in ExperimentalRead more